ClinicalTrials.gg
CompletedNCT02302716ELEMENT 5Updated Oct 24, 2017Results posted

A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus

A Phase 3 interventional study of LY2963016 and LANTUS® in Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company. Completed at 44 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-10-24.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
493
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 — 4 open to participants now, 6 under way, 1 of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 2.

Enrollment
48th of 175
493 · median 253
Started
2014
with 7 others
Phase 3
60 of 176
1 open now
Registered
119th of 176
by date
Lead sponsor
15 of 176
Eli Lilly and Company

Among the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, this one is the 48th largest by enrollment of the 175 interventional ones that give a count, is one of 8 that started in 2014, is one of 60 in phase 3, and was the 119th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About Insulin Glargine

Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the safety and efficacy of the study drug known as LY2963016 as compared to LANTUS® in adults with type 2 diabetes mellitus who are on 2 or more oral antihyperglycemic medications (OAMs).

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have type 2 diabetes mellitus (T2DM).
  • Have been receiving 2 or more OAMs at stable doses for the 12 weeks prior to screening, with or without basal insulin.
  • If currently on basal insulin, must be taking LANTUS® QD or NPH or insulin detemir either QD or twice a day for at least 90 days prior to study entry.
  • Have an ≥7.0% and ≤11.0% if insulin naïve; if previously on basal insulin, then HbA1c ≤11.0%.
  • (BMI) ≤45 kilograms per meter squared (kg/m\^2).
  • As determined by the investigator, are capable and willing to do the following:

    • perform self monitored blood glucose (SMBG)
    • complete participant diaries as instructed
    • are receptive to diabetes education
    • comply with required study treatment and study visits

Exclusion criteria

Exclusion Criteria:

  • Have been on LANTUS® more than once daily within the previous 30 days.
  • Have used any other insulin except the entry insulin [LANTUS®, insulin detemir, or NPH] including commercial (includes any premixed insulins) and insulins within the previous 30 days.
  • Have been exposed to a biosimilar insulin glargine within the previous 90 days.
  • Have participated in a LY2963016 study.
  • Have taken basal plus mealtime insulin (basal bolus therapy) within the last year for greater than 4 continuous weeks.
  • Have used any glucagon like peptide (GLP-1) receptor agonists within the previous 90 days.
  • Have used pramlintide within the previous 30 days.
  • Have excessive insulin resistance at study entry (total insulin dose ≥1.5 units/kg).
  • Have more than 1 episode of severe hypoglycemia within 6 months prior to screening.
  • Have had 2 or more emergency room visits or hospitalizations due to poor glucose control in the 6 months prior to screening.
  • Have known or allergy to LANTUS® or its .
  • Are receiving chronic (lasting longer than 14 consecutive days) systemic therapy or have received such therapy within 4 weeks immediately preceding screening.
  • Have obvious signs or symptoms, or laboratory evidence, of liver disease.
  • Have one of the following concomitant diseases: significant cardiac (e.g., congestive heart failure Class III or IV) or gastrointestinal disease (e.g., significant gastroparesis).
  • Have a history of renal transplantation or are currently receiving renal dialysis.
  • Have a serum creatinine greater than 2.0 milligrams/deciliter (177 micromoles/liter).
  • Have had a blood transfusion or severe blood loss within 3 months prior to screening or have known hemoglobinopathy, hemolytic anemia, or sickle cell anemia.
  • Participants with active cancer or personal history of cancer within the previous 5 years (with the exception of basal cell carcinoma or carcinoma in situ).
  • Have a history or diagnosis of (HIV) infection.
  • Have any other condition (including known drug or alcohol abuse or psychiatric disorder including dementia) that precludes the participant from following and completing the protocol.
  • Are pregnant or intend to become pregnant during the course of the study.
  • Women who are breastfeeding.
  • Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an investigational product or non-approved use of a drug or device other than LY2963016, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
493 participants (actual)

Study arms

  • Experimental
    LY2963016

    Insulin naive participants started on 10 units (U) LY2963016 given subcutaneously (SC) once a day (QD) for 24 weeks. Participants entering the study on LANTUS®, insulin detemir or neutral protamine hagedorn (NPH) QD will begin the study at their current dose SC. Participants will self titrate LY2963016 based on fasting blood glucose (FBG). Participants entering on insulin detemir or NPH twice a day will be started at 80% of the total daily dose SC. Participants will continue oral antihyperglycemic medication (OAM).

    Drug: LY2963016 · Drug: Oral Antihyperglycemic Medication

  • Active comparator
    LANTUS®

    Insulin naive participants started on 10 U LANTUS® given SC QD for 24 weeks. Participants entering the study on LANTUS®, insulin detemir or NPH QD will be started at the same dose SC. Participants entering on insulin detemir or NPH twice a day will be started at 80% of the total daily dose SC. Participants will self titrate LANTUS® based on FBG. Participants will continue OAM.

    Drug: LANTUS® · Drug: Oral Antihyperglycemic Medication

Interventions

  • Administered SC

  • Administered SC

  • DrugOral Antihyperglycemic Medication

    Administered as per standard-of-care.

06

What researchers measure

Primary outcomes

  1. Change From Baseline to 24 Weeks in Hemoglobin A1c (HbA1c)

    HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with baseline of response, treatment (LY2963016, LANTUS), pooled country, basal insulin at entry (yes/no), sulfonylurea (SU) use (yes/no), visit, treatment and visit\*treatment in the model.

    Time frame: Baseline, 24 weeks

Secondary outcomes

  1. Percentage of Participants With HbA1c <7% and ≤6.5%

    Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time.

    Time frame: Endpoint [up to 24 weeks]

  2. Change From Baseline in 7-point Self-Monitored Blood Glucose (SMBG) Values

    Seven-point SMBG are completed at the following timepoints: Before Morning Meal, 2 Hours After Morning Meal, Before Mid-Day Meal, 2 Hours After Mid-Day Meal, Before Evening Meal, Bed Time and 03:00 AM hours. Least Squares (LS) means was determined by mixed model repeated measures (MMRM) methodology with baseline HbA1c, country, sulfonylurea use, basal insulin status at study entry, visit, treatment and visit\*treatment in the model.

    Time frame: Baseline, Week 24

  3. Intra-Participant Variability in Fasting Blood Glucose (FBG)

    Fasting blood glucose (FBG) is a test to determine how much glucose (sugar) is in a blood sample after an overnight fast. Intra-Participant FBG variability was calculated based on the standard deviation (SD) of the morning pre-meal BG value. Least Squares (LS) means was determined by mixed model repeated measures (MMRM) methodology with baseline HbA1c, country, sulfonylurea use, basal insulin status at study entry, visit, treatment and visit\*treatment in the model.

    Time frame: Week 24

  4. Basal Insulin Dose Units Per Day

    Units of Basal Insulin dose taken per day (U/day). Least Squares (LS) means was determined by mixed model repeated measures (MMRM) methodology with baseline of response, baseline HbA1c, country, sulfonylurea use, basal insulin status at study entry, visit, treatment and visit\*treatment in the model.

    Time frame: Week 24

  5. Basal Insulin Dose Per Body Weight (U/kg/Day)

    Basal Insulin dose in units (U) per body weight in kilograms (kg) per day. Least Squares (LS) means was determined by mixed model repeated measures (MMRM) methodology with baseline of response, baseline HbA1c, country, sulfonylurea use, basal insulin status at study entry, visit, treatment and visit\*treatment in the model.

    Time frame: Week 24

  6. Change From Baseline to 24 Weeks in Body Weight

    Change from baseline in body weight. Least Squares (LS) means was determined by mixed model repeated measures (MMRM) methodology with baseline of response, baseline HbA1c, country, sulfonylurea use, basal insulin status at study entry, visit, treatment and visit\*treatment in the model.

    Time frame: Baseline, 24 Weeks

  7. Insulin Treatment Satisfaction Questionnaire (ITSQ) Score

    ITSQ is a validated instrument containing 22 items that assess treatment satisfaction for participants with diabetes and on insulin. Items divided into 5 domains of satisfaction: Inconvenience of Regimen \[(IR) 5 items: domain scores range (DSR) 5-35\], Lifestyle Flexibility \[(LF) 3 items: DSR 3-21\], Glycemic Control \[(GC) 3 items: DSR 3-21\], Hypoglycemic Control \[(HC) 5 items: DSR 5-35\], Insulin Delivery Device \[(IDD) 6 items: DSR 6-42\]. All items measured on a 7-point scale: 1 (no bother at all) to 7 (a tremendous bother), with lower scores reflecting better outcomes. ITSQ Total Overall Raw Scores range from 22-154. Both raw domain and overall scores are transformed on a scale of 0-100, where transformed score=100\*\[(7-mean raw score)/6\]. Higher scores indicate better treatment satisfaction. LS means was determined by MMRM with baseline of response, baseline HbA1c, country, sulfonylurea use, basal insulin status at study entry, visit, treatment and visit\*treatment in the model.

    Time frame: Week 4 and Week 24

  8. Percentage of Participants With Detectable Anti-Drug Antibodies to LY2963016 or LANTUS®

    The percentage of participants with detected insulin antibodies were summarized as counts and percentages at baseline, at each visit, at the 24-week endpoint (LOCF), and overall for the 24-week treatment period.

    Time frame: Endpoint [up to 24 weeks]

  9. Rate of Hypoglycemic Events Adjusted Per 1 Year

    The rate of hypoglycemic events were analyzed at baseline, titration, maintenance, and overall study periods and at endpoint using the Wilcoxon test. In addition, a negative binomial model was used as a sensitivity analysis. A hypoglycemic event is defined as any time a participant has a blood glucose (BG) level of ≤70 milligrams per deciliter (mg/dL) even if the event was not associated with signs, symptoms, or treatment consistent with current guidelines (American Diabetes Association 2005). Nocturnal hypoglycemia is defined as any hypoglycemic event that occurs between bedtime and waking. Severe hypoglycemia is defined as a hypoglycemic event requiring assistance of another person to actively administer carbohydrates, glucagons, or other resuscitative actions. Severe Hypoglycemic events may or may not have a reported BG ≤70 mg/dL. These events may be associated with sufficient neuroglycopenia to induce seizure or coma.

    Time frame: Baseline through Endpoint [up to 24 weeks]

  10. Percentage of Participants With Hypoglycemic Events

    The percentage of participants (with at least 1 hypoglycemic event (total, severe, nocturnal, and others) or incidence during the study was analyzed using Fisher's exact test. A hypoglycemic event is defined as any time a participant has a blood glucose (BG) level of ≤70 milligrams per deciliter (mg/dL) even if the event was not associated with signs, symptoms, or treatment consistent with current guidelines (American Diabetes Association 2005). Nocturnal hypoglycemia is defined as any hypoglycemic event that occurs between bedtime and waking. Severe hypoglycemia is defined as a hypoglycemic event requiring assistance of another person to actively administer carbohydrates, glucagons, or other resuscitative actions. Severe Hypoglycemic events may or may not have a reported BG ≤70 mg/dL. These events may be associated with sufficient neuroglycopenia to induce seizure or coma.

    Time frame: Endpoint [up to 24 weeks]

07

Results

Posted Oct 24, 2017

Participant flow

Participant flow — Overall Study
MilestoneLY2963016LANTUS®
Started249244
Received at least 1 dose of study drug249244
Completed230225
Not completed1919
Withdrew: Adverse event11
Withdrew: Death01
Withdrew: Lack of efficacy01
Withdrew: Lost to follow-up24
Withdrew: Physician decision34
Withdrew: Withdrawal by subject137
Withdrew: Protocol violation01

Outcome measures

PrimaryChange From Baseline to 24 Weeks in Hemoglobin A1c (HbA1c)

HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with baseline of response, treatment (LY2963016, LANTUS), pooled country, basal insulin at entry (yes/no), sulfonylurea (SU) use (yes/no), visit, treatment and visit\*treatment in the model.

Time frame:
Baseline, 24 weeks
Reported as:
Least squares mean · Percentage of glycosylated hemoglobin
Change From Baseline to 24 Weeks in Hemoglobin A1c (HbA1c)
Percentage of glycosylated hemoglobinLY2963016LANTUS®
Change From Baseline to 24 Weeks in Hemoglobin A1c (HbA1c)-1.25 ± 0.066-1.22 ± 0.067
Statistical analysis
  • LY2963016 vs LANTUS® · Mixed Models Analysis · p = 0.693 · Mean difference (final values): -0.04 · 95% CI -0.22 to 0.15
SecondaryPercentage of Participants With HbA1c <7% and ≤6.5%

Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time.

Time frame:
Endpoint [up to 24 weeks]
Reported as:
Number · Percentage of participants
Percentage of Participants With HbA1c <7% and ≤6.5%
Percentage of participantsLY2963016LANTUS®
HbA1c- at 24 week endpoint (LOCF) < 7.0%35.038.3
HbA1c- at 24 week endpoint (LOCF) <= 6.5%20.818.8
SecondaryChange From Baseline in 7-point Self-Monitored Blood Glucose (SMBG) Values

Seven-point SMBG are completed at the following timepoints: Before Morning Meal, 2 Hours After Morning Meal, Before Mid-Day Meal, 2 Hours After Mid-Day Meal, Before Evening Meal, Bed Time and 03:00 AM hours. Least Squares (LS) means was determined by mixed model repeated measures (MMRM) methodology with baseline HbA1c, country, sulfonylurea use, basal insulin status at study entry, visit, treatment and visit\*treatment in the model.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · Millimoles per liter (mmol/L)
Change From Baseline in 7-point Self-Monitored Blood Glucose (SMBG) Values
Millimoles per liter (mmol/L)LY2963016LANTUS®
24 week- Before Morning Meal-2.37 ± 0.083-2.69 ± 0.083
24 week- 2 Hours After Morning Meal-2.78 ± 0.161-3.00 ± 0.160
24 week-Before Mid-Day Meal-2.14 ± 0.135-2.20 ± 0.132
24 weeks- 2 Hours After Mid-Day Meal-2.26 ± 0.158-2.42 ± 0.156
24 weeks-Before Evening Meal-1.84 ± 0.156-2.25 ± 0.154
24 weeks- Bed Time-2.14 ± 0.157-2.40 ± 0.156
24 weeks- 3:00 AM hrs-2.09 ± 0.124-2.09 ± 0.122
SecondaryIntra-Participant Variability in Fasting Blood Glucose (FBG)

Fasting blood glucose (FBG) is a test to determine how much glucose (sugar) is in a blood sample after an overnight fast. Intra-Participant FBG variability was calculated based on the standard deviation (SD) of the morning pre-meal BG value. Least Squares (LS) means was determined by mixed model repeated measures (MMRM) methodology with baseline HbA1c, country, sulfonylurea use, basal insulin status at study entry, visit, treatment and visit\*treatment in the model.

Time frame:
Week 24
Reported as:
Least squares mean · mmol/L
Intra-Participant Variability in Fasting Blood Glucose (FBG)
mmol/LLY2963016LANTUS®
Intra-Participant Variability in Fasting Blood Glucose (FBG)0.81 ± 0.0490.79 ± 0.049
SecondaryBasal Insulin Dose Units Per Day

Units of Basal Insulin dose taken per day (U/day). Least Squares (LS) means was determined by mixed model repeated measures (MMRM) methodology with baseline of response, baseline HbA1c, country, sulfonylurea use, basal insulin status at study entry, visit, treatment and visit\*treatment in the model.

Time frame:
Week 24
Reported as:
Least squares mean · Units per day (U/day)
Basal Insulin Dose Units Per Day
Units per day (U/day)LY2963016LANTUS®
Basal Insulin Dose Units Per Day49.8 ± 2.1649.7 ± 2.17
SecondaryBasal Insulin Dose Per Body Weight (U/kg/Day)

Basal Insulin dose in units (U) per body weight in kilograms (kg) per day. Least Squares (LS) means was determined by mixed model repeated measures (MMRM) methodology with baseline of response, baseline HbA1c, country, sulfonylurea use, basal insulin status at study entry, visit, treatment and visit\*treatment in the model.

Time frame:
Week 24
Reported as:
Least squares mean · units per kilogram per day (U/kg/day)
Basal Insulin Dose Per Body Weight (U/kg/Day)
units per kilogram per day (U/kg/day)LY2963016LANTUS®
Basal Insulin Dose Per Body Weight (U/kg/Day)0.58 ± 0.0240.61 ± 0.024
SecondaryChange From Baseline to 24 Weeks in Body Weight

Change from baseline in body weight. Least Squares (LS) means was determined by mixed model repeated measures (MMRM) methodology with baseline of response, baseline HbA1c, country, sulfonylurea use, basal insulin status at study entry, visit, treatment and visit\*treatment in the model.

Time frame:
Baseline, 24 Weeks
Reported as:
Least squares mean · Kilogram (kg)
Change From Baseline to 24 Weeks in Body Weight
Kilogram (kg)LY2963016LANTUS®
Change From Baseline to 24 Weeks in Body Weight2.3 ± 0.281.7 ± 0.29
SecondaryInsulin Treatment Satisfaction Questionnaire (ITSQ) Score

ITSQ is a validated instrument containing 22 items that assess treatment satisfaction for participants with diabetes and on insulin. Items divided into 5 domains of satisfaction: Inconvenience of Regimen \[(IR) 5 items: domain scores range (DSR) 5-35\], Lifestyle Flexibility \[(LF) 3 items: DSR 3-21\], Glycemic Control \[(GC) 3 items: DSR 3-21\], Hypoglycemic Control \[(HC) 5 items: DSR 5-35\], Insulin Delivery Device \[(IDD) 6 items: DSR 6-42\]. All items measured on a 7-point scale: 1 (no bother at all) to 7 (a tremendous bother), with lower scores reflecting better outcomes. ITSQ Total Overall Raw Scores range from 22-154. Both raw domain and overall scores are transformed on a scale of 0-100, where transformed score=100\*\[(7-mean raw score)/6\]. Higher scores indicate better treatment satisfaction. LS means was determined by MMRM with baseline of response, baseline HbA1c, country, sulfonylurea use, basal insulin status at study entry, visit, treatment and visit\*treatment in the model.

Time frame:
Week 4 and Week 24
Reported as:
Least squares mean · units on a scale
Insulin Treatment Satisfaction Questionnaire (ITSQ) Score
units on a scaleLY2963016LANTUS®
IR-Week 485.79 ± 1.3284.92 ± 1.33
IR-Week 2484.75 ± 1.2684.91 ± 1.28
LF-Week 471.43 ± 1.8769.11 ± 1.89
LF-Week 2472.44 ± 1.7770.87 ± 1.80
HC-Week 477.82 ± 1.5076.98 ± 1.52
HC-Week 2476.18 ± 1.4676.52 ± 1.48
GC-Week 479.24 ± 1.4578.87 ± 1.46
GC-Week 2482.14 ± 1.3681.30 ± 1.38
IDD-Week 482.21 ± 1.2382.37 ± 1.25
IDD-Week 2482.12 ± 1.2982.01 ± 1.31
ITSQ Overall Total-Week 480.15 ± 1.1279.40 ± 1.13
ITSQ Overall Total-Week 2480.01 ± 1.1379.76 ± 1.14
SecondaryPercentage of Participants With Detectable Anti-Drug Antibodies to LY2963016 or LANTUS®

The percentage of participants with detected insulin antibodies were summarized as counts and percentages at baseline, at each visit, at the 24-week endpoint (LOCF), and overall for the 24-week treatment period.

Time frame:
Endpoint [up to 24 weeks]
Reported as:
Number · Percentage of participants
Percentage of Participants With Detectable Anti-Drug Antibodies to LY2963016 or LANTUS®
Percentage of participantsLY2963016LANTUS®
Percentage of Participants With Detectable Anti-Drug Antibodies to LY2963016 or LANTUS®14.517.2
SecondaryRate of Hypoglycemic Events Adjusted Per 1 Year

The rate of hypoglycemic events were analyzed at baseline, titration, maintenance, and overall study periods and at endpoint using the Wilcoxon test. In addition, a negative binomial model was used as a sensitivity analysis. A hypoglycemic event is defined as any time a participant has a blood glucose (BG) level of ≤70 milligrams per deciliter (mg/dL) even if the event was not associated with signs, symptoms, or treatment consistent with current guidelines (American Diabetes Association 2005). Nocturnal hypoglycemia is defined as any hypoglycemic event that occurs between bedtime and waking. Severe hypoglycemia is defined as a hypoglycemic event requiring assistance of another person to actively administer carbohydrates, glucagons, or other resuscitative actions. Severe Hypoglycemic events may or may not have a reported BG ≤70 mg/dL. These events may be associated with sufficient neuroglycopenia to induce seizure or coma.

Time frame:
Baseline through Endpoint [up to 24 weeks]
Reported as:
Mean · Hypoglycemic events per 1 year
Rate of Hypoglycemic Events Adjusted Per 1 Year
Hypoglycemic events per 1 yearLY2963016LANTUS®
Total Hypoglycemia with BG ≤70 mg/dL16.95 ± 23.44423.37 ± 35.809
Severe Hypoglycemia0.00 ± 0.000.00 ± 0.02
Nocturnal Hypoglycemia with BG ≤70 mg/dL6.64 ± 11.6507.94 ± 17.882
SecondaryPercentage of Participants With Hypoglycemic Events

The percentage of participants (with at least 1 hypoglycemic event (total, severe, nocturnal, and others) or incidence during the study was analyzed using Fisher's exact test. A hypoglycemic event is defined as any time a participant has a blood glucose (BG) level of ≤70 milligrams per deciliter (mg/dL) even if the event was not associated with signs, symptoms, or treatment consistent with current guidelines (American Diabetes Association 2005). Nocturnal hypoglycemia is defined as any hypoglycemic event that occurs between bedtime and waking. Severe hypoglycemia is defined as a hypoglycemic event requiring assistance of another person to actively administer carbohydrates, glucagons, or other resuscitative actions. Severe Hypoglycemic events may or may not have a reported BG ≤70 mg/dL. These events may be associated with sufficient neuroglycopenia to induce seizure or coma.

Time frame:
Endpoint [up to 24 weeks]
Reported as:
Number · Percentage of participants
Percentage of Participants With Hypoglycemic Events
Percentage of participantsLY2963016LANTUS®
Total hypoglycemia with BG ≤70 mg/dL68.769.1
Severe hypoglycemia00.8
Nocturnal hypoglycemia with BG ≤70 mg/dL49.646.1
Non-nocturnal hypoglycemia with BG ≤70 mg/dL59.463.0

Adverse events

Collected over Up to 28 weeks. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LY2963016—10/249 (4%)75/249 (30.1%)
LANTUS®—12/244 (4.9%)87/244 (35.7%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventLY2963016LANTUS®
PneumoniaInfections and infestations0/2492/244
HypoglycaemiaMetabolism and nutrition disorders1/2492/244
Acute myocardial infarctionCardiac disorders0/2491/244
Cardiogenic shockCardiac disorders0/2491/244
Myocardial infarctionCardiac disorders0/2491/244
Supraventricular tachycardiaCardiac disorders0/2491/244
Macular holeEye disorders0/2491/244
BronchitisInfections and infestations0/2491/244
DiverticulitisInfections and infestations0/2491/244
Head injuryInjury, poisoning and procedural complications0/2491/244
Most frequent other events
Showing 10 of 27
Most frequent other events
EventLY2963016LANTUS®
NasopharyngitisInfections and infestations18/24924/244
Upper respiratory tract infectionInfections and infestations10/2499/244
Weight increasedInvestigations8/2494/244
Injection site painGeneral disorders2/2497/244
ArthralgiaMusculoskeletal and connective tissue disorders3/2497/244
Abnormal weight gainMetabolism and nutrition disorders7/2495/244
Muscle spasmsMusculoskeletal and connective tissue disorders3/2495/244
HeadacheNervous system disorders4/2495/244
Oropharyngeal painRespiratory, thoracic and mediastinal disorders1/2495/244
VomitingGastrointestinal disorders2/2494/244

Baseline characteristics

All randomized participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)LY2963016LANTUS®Total
Mean57.82 ± 8.8356.98 ± 9.8657.40 ± 9.35
Sex: Female, Male
Sex: Female, Male(Participants)LY2963016LANTUS®Total
Female118118236
Male131126257
Race (NIH/OMB)
Race (NIH/OMB)(Participants)LY2963016LANTUS®Total
American Indian or Alaska Native101
Asian116118234
Native Hawaiian or Other Pacific Islander000
Black or African American151530
White115110225
More than one race213
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)LY2963016LANTUS®Total
South Korea474592
Puerto Rico293362
Turkey151025
United States6057117
Taiwan202242
India4951100
Russia292655
Baseline Hemoglobin A1c (HbA1c)
Baseline Hemoglobin A1c (HbA1c)(Percentage of glycosylated hemoglobin)LY2963016LANTUS®Total
Mean8.66 ± 1.098.56 ± 1.028.61 ± 1.06
Sulfonylurea Group
Sulfonylurea Group(Participants)LY2963016LANTUS®Total
Yes, did use sulfonylurea207207414
No, did not use sulfonylurea423779
Duration of Diabetes
Duration of Diabetes(years)LY2963016LANTUS®Total
Mean11.59 ± 6.3412.26 ± 6.4511.92 ± 6.40
Time of basal insulin injection
Time of basal insulin injection(Participants)LY2963016LANTUS®Total
Daytime9996195
Evening/Bedtime150148298
08

Study locations

44 sites
  • New Horizon Research Center
    Miami, Florida 33175, United States
  • Suncoast Clinical Research
    New Port Richey, Florida 34652, United States
  • Atlanta Vanguard Medical Associates
    Smyrna, Georgia 30082, United States
  • Cotton O'Neil Clinic
    Topeka, Kansas 66606, United States
  • Manhattan Medical Research
    New York, New York 10016, United States
  • Aventiv Research
    Columbus, Ohio 43213, United States
  • University Diabetes and Endocrine Consultants
    Chattanooga, Tennessee 37411, United States
  • Dallas Diabetes Endocrine Center
    Dallas, Texas 75230, United States
  • Advanced Research Institute
    South Ogden, Utah 84405, United States
  • Tacoma Center for Arthritis Research, PS
    Tacoma, Washington 98405, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ahmedabad, 380007, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chennai, 600086, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hyderabad, 500 012, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Jaipur, 302020, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kormangala, 560034, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mumbai, 40016, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    New Delhi, 110060, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Panaji, 403001, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Pune, 411001, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Secunderabad, 500033, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Visakhapatnam, 530002, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ansan-Si, 425-707, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bucheon, 420-717, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Daegu, 700-712, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Goyang-Si, 410-719, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Goyang, 411-706, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Jeju City, 690-767, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Pusan, 602-739, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Seoul, 139-872, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Suwon, 442-723, Korea, Republic of
  • Manati Center for Clinical Research Inc
    Manati, 00674, Puerto Rico
  • American Telemedicine Center
    San Juan, 00917, Puerto Rico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Cheboksary, 428000, Russian Federation
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Saratov, 410053, Russian Federation
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    St. Petersburg, 192012, Russian Federation
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sindian City, 23148, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Taichung, 40201, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Taichung, 40447, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Taichung, 433, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Taipei, 10508, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ankara, 6110, Turkey
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Antalya, 07059, Turkey
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Gaziantep, 27310, Turkey
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Istanbul, 34865, Turkey
09

References and documents

Publications

  • Mohan V, Ahn KJ, Cho YM, Sahay RK, Huang CN, Kalra S, Chadha M, Bhattacharya I, Kim SY, Spaepen E. Lilly Insulin Glargine Versus Lantus(R) in Type 2 Diabetes Mellitus Patients: India and East Asia Subpopulation Analyses of the ELEMENT 5 Study. Clin Drug Investig. 2019 Aug;39(8):745-756. doi: 10.1007/s40261-019-00798-1. PubMed 31119716 ↗
  • Pollom RK, Ilag LL, Lacaya LB, Morwick TM, Ortiz Carrasquillo R. Lilly Insulin Glargine Versus Lantus(R) in Insulin-Naive and Insulin-Treated Adults with Type 2 Diabetes: A Randomized, Controlled Trial (ELEMENT 5). Diabetes Ther. 2019 Feb;10(1):189-203. doi: 10.1007/s13300-018-0549-3. Epub 2019 Jan 2. PubMed 30604091 ↗

Individual participant data

Plan to share: Yes — Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com. This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2014, a primary completion of Jul 2016 and a completion of Jul 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2017, 1 year 3 months after primary completion. A results delay was requested in Dec 2016.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2014
First posted
Nov 27, 2014
Start
Dec 2014
Primary completionActual
Jul 2016
CompletionActual
Jul 2016
Results delay requested
Dec 21, 2016
Results first posted
Oct 24, 2017
Last update
Oct 24, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 24, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02302716
Responsible party
Sponsor
First posted
Nov 27, 2014
Start date
Dec 2014
Primary completion
Jul 2016
Completion
Jul 2016
Results posted
Oct 24, 2017
Last update
Oct 24, 2017

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin Glargine

Start the discussion